Adamax

Overview

Adamax is a grey-market nootropic peptide developed and sold by the Mexico-based vendor Ceretropic. It is marketed as a Semax derivative: N-acetyl Semax amide (Ac-MEHFPGP-NH2) with an adamantane (adamantyl-glycine) moiety appended at the C-terminus, reportedly intended to improve metabolic stability and blood-brain-barrier penetration. It is NOT an ADNP / NAP / davunetide analog despite some online descriptions conflating it with those compounds. Adamax has no indexed peer-reviewed literature of its own; all claimed effects are extrapolated from Semax data plus anecdotal user reports.

Mechanism of Action

Mechanism is assumed rather than demonstrated. By analogy with the parent peptide Semax (a heptapeptide ACTH(4–10) analog, Met-Glu-His-Phe-Pro-Gly-Pro), Adamax is proposed to modulate BDNF/NGF expression and monoaminergic tone in the CNS. The added adamantane group is presumed to protect against exopeptidase degradation and increase lipophilicity / BBB permeability, but no pharmacokinetic or pharmacodynamic data specific to Adamax have been published.

Research Summary

No peer-reviewed, PubMed-indexed studies exist for Adamax specifically. Evidence base is essentially limited to vendor marketing copy and anecdotal forum reports (e.g., discussions around the original Ceretropic release). Claims of cognitive enhancement, neurogenesis, or neuroprotection are extrapolations from the Semax literature and have NOT been validated for Adamax as a distinct compound. Not FDA-approved. Strictly a grey-market research chemical; safety and efficacy in humans are unknown.

Vendors selling Adamax

Scored vendors carrying Adamax, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Unknown in humans; no published safety data
• Anecdotal reports: headache, overstimulation, insomnia, mild nasal irritation (with intranasal use)

Frequently asked questions

Has Adamax been independently lab-tested?

Disclosed Labs has collected 8 Certificates of Analysis (COA) for Adamax from 3 independent testing labs. 5 vendors have submitted material for testing. Products average 99.8% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/adamax/testing.

What is the average purity of Adamax on the market?

Based on 8 COAs analyzed by Disclosed Labs, Adamax products average 99.8% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/adamax/coas.

Which labs have tested Adamax?

Independent labs that have tested Adamax include: ILS Labs (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

Where can researchers source Adamax?

6 vendors with Disclosed Labs trust grades currently list Adamax, including Glacier Aminos, Orbitrex Peptides, Real Peptides. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/adamax.

How does Adamax work?

Mechanism is assumed rather than demonstrated. By analogy with the parent peptide Semax (a heptapeptide ACTH(4–10) analog, Met-Glu-His-Phe-Pro-Gly-Pro), Adamax is proposed to modulate BDNF/NGF expression and monoaminergic tone in the CNS. The added adamantane group is presumed to protect against exopeptidase degradation and increase lipophilicity / BBB permeability, but no pharmacokinetic or pharmacodynamic data specific to Adamax have been published.

What does the research say about Adamax?

No peer-reviewed, PubMed-indexed studies exist for Adamax specifically. Evidence base is essentially limited to vendor marketing copy and anecdotal forum reports (e.g., discussions around the original Ceretropic release). Claims of cognitive enhancement, neurogenesis, or neuroprotection are extrapolations from the Semax literature and have NOT been validated for Adamax as a distinct compound. Not FDA-approved. Strictly a grey-market research chemical; safety and efficacy in humans are unknown.